Standout Papers

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes 2013 2026 2017 2021 7.8k
  1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (2015)
    Bernard Zinman, Christoph Wanner et al. New England Journal of Medicine
  2. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes (2016)
    Christoph Wanner, Silvio E. Inzucchi et al. New England Journal of Medicine
  3. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus (2013)
    David Z.I. Cherney, Bruce A. Perkins et al. Circulation
  4. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk (2018)
    Julio Rosenstock, Vlado Perkovic et al. JAMA
  5. How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial (2017)
    Silvio E. Inzucchi, Bernard Zinman et al. Diabetes Care
  6. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes (2019)
    Julio Rosenstock, Steven E. Kahn et al. JAMA
  7. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus (2014)
    David Z.I. Cherney, Bruce A. Perkins et al. Cardiovascular Diabetology
  8. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes (2015)
    Robert Ćhilton, I. Tikkanen et al. Diabetes Obesity and Metabolism
  9. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial (2019)
    David Fitchett, Silvio E. Inzucchi et al. Circulation

Immediate Impact

1 from Science/Nature 145 standout
Sub-graph 1 of 13

Citing Papers

Type 2 diabetes
2022 Standout
Gliflozins in the Management of Cardiovascular Disease
2022 Standout
87 intermediate papers

Works of Odd Erik Johansen being referenced

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
and 20 more

Author Peers

Author Last Decade Papers Cites
Odd Erik Johansen 14296 6166 5659 118 17.1k
Ofri Mosenzon 12734 4655 5245 140 15.1k
David Fitchett 12416 6610 5125 198 18.0k
Uli C. Broedl 18132 8994 8145 117 22.4k
Michaela Mattheus 11062 4754 4439 80 13.1k
Hans J. Woerle 11126 5444 5008 88 12.9k
Stefan Hantel 9082 4555 3893 62 13.3k
David Z.I. Cherney 10214 4801 3528 323 14.1k
Maximilian von Eynatten 7968 3409 3119 114 10.7k
Giancarlo Viberti 6457 2048 3638 189 13.4k
Marc P. Bonaca 6800 5664 3047 273 14.6k

All Works

Loading papers...

Rankless by CCL
2026